Abstract
Background
Two pharmacokinetic studies were performed to investigate whether there is any interaction between etonogestrel or ethinylestradiol released from the combined contraceptive vaginal ring NuvaRing® and concomitant treatment with orally administered amoxicillin or doxycycline.
Methods
In one study, healthy women were randomised to receive either NuvaRing® alone for 21 days or NuvaRing® for 21 days plus amoxicillin on days 1–10. After a 7-day ring-free washout period, women were crossed over to the alternate regimen for a further 21-day treatment period. The other study used an identical design except that women received doxycycline instead of amoxicillin. The amoxicillin study measured serum etonogestrel and ethinylestradiol levels and area under the serum concentration-time curve (AUC) values over the initial 12 hours on days 1 (AUC12) and 10 (AUCrr216-228) and the whole of days 1–11 (AUC240) and 1–22 (AUC504). The doxycycline study measured AUC values over the initial 24 hours on days 1 (AUCrr24) and 10 (AUCrr216-240) and the whole of days 1–11 (AUC240) and 1–22 (AUCrr504).
Results
No differences in etonogestrel or ethinylestradiol serum concentrations were observed between subjects using NuvaRing® alone versus those receiving the ring plus either of the antibiotics. Calculation of etonogestrel and ethinylestradiol interaction/control ratios confirmed the absence of pharmacokinetic interactions.
Conclusion
The results from these studies demonstrate the absence of pharmacokinetic interactions between etonogestrel and ethinylestradiol released from NuvaRing® and the oral antibiotics amoxicillin and doxycycline, suggesting that contraceptive efficacy would also be unaffected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39: 233–42
Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100: 585–93
Novak A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003; 67: 187–94
Sparrow MJ. Pill method failures. N Z Med J 1987; 100: 102–5
Back DJ, Grimmer SF, Orme ML, et al. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527–32
Shenfield GM. Oral contraceptives: are drug interactions of clinical significance? Drug Saf 1993; 9: 21–37
Stockley IH. Antibiotics and oral contraceptive failure: an update. Pharm J 1982; 229: 525–8
Zhanel GG, Siemens S, Slayter K, et al. Antibiotic and oral contraceptive drug interactions: is there a need for concern? Can J Infect Dis 1999; 10: 429–33
DeRossi SS, Hersh EV. Antibiotics and oral contraceptives. Dent Clin North Am 2002; 46: 653–64
Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review. Contraception 1999; 59: 71–8
Dickinson BD, Altaian RD, Nielsen NH, et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001; 98: 853–60
Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46: 917–23
In Vivo Metabolic Drug-Drug Interaction Working Group, US Department of Health and Human Services, Food and Drug Administration. In vivo drug metabolism/drug interaction studies: study design, data analysis, and recommendations for dosing and labelling, 1999 [online]. Available from URL: http://www.fda.gov/cder/guidance/2635fnl.htm#P116_5854 [Accessed 2005 Feb 2]
Roumen FJ, Apter D, Mulders TM, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001; 16: 469–75
Electronic Medicines Compendium. Summary of product characteristics: amoxil capsules [online]. Available from URL: http://www.medicines.org.uk [Accessed 2005 Feb 2]
Physician’s Desk Reference. 56th ed. Montvale (NJ): Medical Economics, 2002: 1855-6
Orme ML, Back DJ. Factors affecting the enterohepatic circulation of oral contraceptive steroids. Am J Obstet Gynecol 1990; 163: 2146–52
Emery MG. Oestrogens and progestins. In: Levy RH, editor. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 511–28
Back DJ, Breckenridge AM, Crawford FE, et al. Reduction of the enterohepatic circulation of norethisterone by antibiotics in the rat: correlation with changes in the gut flora. J Steroid Biochem 1980; 13: 95–100
Abrams LS, Skee D, Natarajan J, et al. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril 2002; 77 Suppl. 2: S3–12
Acknowledgements
This study was supported by NV Organon. P. Dogterom and M. van den Heuvel are employees of NV Organon. The authors wish to acknowledge the following people who were involved in the design of this trial: Claudia van den Berg, Moki Vree and Elenie van Vliet-Daskalopoulou.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dogterom, P., van den Heuvel, M.W. & Thomsen, T. Absence of Pharmacokinetic Interactions of the Combined Contraceptive Vaginal Ring NuvaRing® with Oral Amoxicillin or Doxycycline in Two Randomised Trials. Clin Pharmacokinet 44, 429–438 (2005). https://doi.org/10.2165/00003088-200544040-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200544040-00007